Stada to go public with potential valuation of €10-12 billion.
PorAinvest
lunes, 17 de marzo de 2025, 7:33 am ET1 min de lectura
BCSF--
Stada, majority-owned by private equity firms Bain Capital and Cinven, has been valued at approximately €10-12bn ($10.87bn-$13.05bn) [1]. The company is renowned for its diverse product range, including popular brands like Grippostad, Ladival, and Silomat [1].
The IPO aims to raise around €1.5bn ($1.63bn) from the sale of shares, which will provide Stada with the necessary funds for future growth and development [1]. Stada's owners, Bain Capital and Cinven, have been preparing for this share sale since taking the company private in 2017 for €5.3bn ($5.77bn) [2].
Stada's IPO comes at a critical time for Europe's equity markets, as investor demand for pharmaceutical stocks remains strong [2]. Andreas Fibig, the new independent chairman of Stada, expressed optimism regarding the potential investor interest [2].
However, the timing of the IPO may still be subject to change. Market conditions and volatility, as indicated by the VIX index, could influence Stada's decision [1]. The exact launch date and the subsequent return to the stock exchange for Stada could also be subject to delay [1].
Despite the potential challenges, Stada's IPO represents an exciting opportunity for the company to establish itself as a leading player in the European pharmaceutical industry.
References:
[1] Reuters. Stada plans to launch IPO as soon as Wednesday, sources say. 4 Feb 2023. https://in.marketscreener.com/quote/index/DAX-7395/news/Stada-plans-to-launch-IPO-as-soon-as-Wednesday-sources-say-49349484/
[2] BNN Bloomberg. Stada CEO sees strong investor demand ahead of top European IPO. 4 Feb 2023. https://www.bnnbloomberg.ca/business/company-news/2025/02/04/stada-ceo-sees-strong-investor-demand-ahead-of-top-european-ipo/
STAA--
Pharma company Stada is preparing for an initial public offering (IPO) in Frankfurt, with an announcement expected soon, possibly on Wednesday. The company, owned by Bain Capital and Cinven, could be valued at around €10-12bn. The IPO would make Stada one of the largest in Europe this year, with a potential listing on the MDax or DAX. The company plans to raise around €1.5bn from the sale of shares.
In a highly anticipated move, German pharma company Stada is preparing to launch its initial public offering (IPO) on the Frankfurt Stock Exchange as soon as Wednesday [1]. This significant event could make Stada one of the largest IPOs in Europe this year, potentially earning a place in the MDax or DAX company index.Stada, majority-owned by private equity firms Bain Capital and Cinven, has been valued at approximately €10-12bn ($10.87bn-$13.05bn) [1]. The company is renowned for its diverse product range, including popular brands like Grippostad, Ladival, and Silomat [1].
The IPO aims to raise around €1.5bn ($1.63bn) from the sale of shares, which will provide Stada with the necessary funds for future growth and development [1]. Stada's owners, Bain Capital and Cinven, have been preparing for this share sale since taking the company private in 2017 for €5.3bn ($5.77bn) [2].
Stada's IPO comes at a critical time for Europe's equity markets, as investor demand for pharmaceutical stocks remains strong [2]. Andreas Fibig, the new independent chairman of Stada, expressed optimism regarding the potential investor interest [2].
However, the timing of the IPO may still be subject to change. Market conditions and volatility, as indicated by the VIX index, could influence Stada's decision [1]. The exact launch date and the subsequent return to the stock exchange for Stada could also be subject to delay [1].
Despite the potential challenges, Stada's IPO represents an exciting opportunity for the company to establish itself as a leading player in the European pharmaceutical industry.
References:
[1] Reuters. Stada plans to launch IPO as soon as Wednesday, sources say. 4 Feb 2023. https://in.marketscreener.com/quote/index/DAX-7395/news/Stada-plans-to-launch-IPO-as-soon-as-Wednesday-sources-say-49349484/
[2] BNN Bloomberg. Stada CEO sees strong investor demand ahead of top European IPO. 4 Feb 2023. https://www.bnnbloomberg.ca/business/company-news/2025/02/04/stada-ceo-sees-strong-investor-demand-ahead-of-top-european-ipo/

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios